GSE203522 dopamine SH-SY5Y 2 v 1 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE203522_dopamine_SH-SY5Y_2_v_1_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE203522_dopamine_SH-SY5Y_2_v_1_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE203522_dopamine_SH-SY5Y_2_v_1_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE203522_dopamine_SH-SY5Y_2_v_1_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

H19 imprinted maternally expressed transcript

Gene

small nucleolar RNA host gene 16

Gene

uncharaterized LOC112694756

Gene

long intergenic non-protein coding RNA 511

Gene

PSMG3 antisense RNA 1

Gene

uncharacterized LOC339260

Gene

MIR210 host gene

Gene

DiGeorge syndrome critical region gene 5

Gene

KCNQ1 opposite strand/antisense transcript 1

Gene

5-hydroxytryptamine receptor 7 pseudogene 1

  • Gene

    H19 imprinted maternally expressed transcript


  • Gene

    small nucleolar RNA host gene 16


  • Gene

    uncharaterized LOC112694756


  • Gene

    long intergenic non-protein coding RNA 511


  • Gene

    PSMG3 antisense RNA 1


  • Gene

    uncharacterized LOC339260



  • Gene

    DiGeorge syndrome critical region gene 5


  • Gene

    KCNQ1 opposite strand/antisense transcript 1


  • Gene

    5-hydroxytryptamine receptor 7 pseudogene 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.